Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Eversight Partners with LighTopTech to Improve Eye Imaging
Eversight has partnered up with LighTopTech to elevate the standards of imaging modalities for eye tissues. This ambitious partnership, spanning over four years, sets out to redefine the landscape of ocular imaging in both clinical and research domains. LighTopTech’s OCX…
CorneaGen Launches CTAK for Keratoconus Patients
CorneaGen, a leading provider of ocular tissue, announced the commercial launch of Corneal Tissue Addition for Keratoplasty (CTAK), a novel solution for corneal contouring in keratoconic eyes. Developed in collaboration with CTAK LLC and Ziemer, CTAK offers patient-ready, gamma-irradiated sterile…
BIOPHTA Secures €6.5M to Advance Eye Disease Therapy
BIOPHTA, a preclinical biotech company, has successfully closed a Seed round, raising €6.5 million to advance its pioneering technology into clinical development for the treatment of glaucoma and macular edema. This significant funding injection, led by prominent European venture capital…
Phase 3 Trial for AZR-MD-001 in MGD Patients Begins
Azura Ophthalmics has reached a significant milestone with the enrollment of the first patient in the ASTRO study—a phase 3 clinical trial evaluating the efficacy and safety of AZR-MD-001 in patients grappling with clinical signs and symptoms of meibomian gland…
Novel Eyeglass Lens Tech Offers Relief for Migraine Patients
This spring, individuals grappling with migraines find relieve with a novel solution for managing light sensitivity, thanks to new eyeglass lens technology developed by a physician-scientist at the University of Utah John A. Moran Eye Center. The Impact of Migraine…
Zeiss Introduces Upgraded Cirrus 6000 OCT
Zeiss Medical Technology has introduced a series of enhancements to the Cirrus 6000, promising a more streamlined and data-centric workflow for ophthalmologists. This update boasts the largest OCT reference database in the US market and fortified cybersecurity features. With recent…
IND for DF-003 Cleared by FDA for ROSAH Syndrome Trial
In a significant development for the medical community, Drug Farm announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug (IND) application of DF-003. This novel drug, hailed as a first-in-class oral medication,…
USC Roski Eye Institute Investigates Promising Drugs for TED
The USC Roski Eye Institute is making significant strides in the realm of Thyroid Eye Disease (TED) treatment through pioneering clinical trials exploring new medications. TED, a condition characterized by bulging eyes and potential vision impairment, has traditionally necessitated multiple…
Tips for Choosing the Right Artificial Tears
Dry eyes can be an irritating and persistent problem for many individuals, leading to discomfort and potential vision issues if left untreated. Artificial tears are a common and effective solution for relieving dry eye symptoms. Dry eye is a common…
European Authorization Granted for Lytenava in Wet AMD
Outlook Therapeutics has achieved a significant milestone with the European Commission granting Marketing Authorization for Lytenava (bevacizumab gamma), an innovative ophthalmic formulation designed for the treatment of wet AMD (Age-related Macular Degeneration). This approval marks a pivotal moment as Lytenava…